logo
Share SHARE
FONT-SIZE Plus   Neg

Derma Sciences Buys Global Long-Term Exclusive Rights To NIMBUS Technology

Derma Sciences Inc. (DSCI) and Quick-Med Technologies Inc. reached an agreement, whereby Quick-Med Technologies has granted Derma Sciences an exclusive global license to intellectual property related to the novel NIMBUS antimicrobial technology, which is available in BIOGUARD dressings.

As per the deal, Derma Sciences would make a $1.3 million upfront payment to Quick-Med Technologies and future milestone payments based on sales of products incorporating the licensed technology. Further, the royalty paid by Derma Sciences to Quick-Med Technologies on such products would be lowered from 20% currently, to a sliding scale starting at 8.5% and declining as sales milestones are achieved.

Sales by Derma Sciences of products covered under this deal were some $1.5 million in 2011, and may grow between 30% and 40% annually, in line with view for the company's advanced wound care product portfolio.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The U.S. Food and Drug Administration Thursday announced it will start regulating all tobacco products, including e-cigarettes, cigars, hookah tobacco and pipe tobacco, just like it regulates cigarettes. Under the new rules, e-cigarettes manufacturers should receive marketing authorization from the... News Corp. (NWS, NWSA) on Thursday posted a loss for the third quarter, hurt largely by lower advertising revenue at news and information segment and a stronger dollar, partly offset by growth in the digital real estate business. The New York-based media company reported a third-quarter loss of $149... Action-sports camera maker GoPro Inc. (GPRO), Thursday posted a loss for the first quarter, as revenues nearly halved and margins dropped sharply reflecting weak demand for its wearable cameras. Loss for the quarter were higher than what Wall Street analysts estimated, but revenues trumped expectations. San...
comments powered by Disqus
Follow RTT